Literature DB >> 9684814

Influence of physical activity on warfarin therapy.

Y Shibata, H Hashimoto, C Kurata, R Ohno, T Kazui, M Takinami.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9684814

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  11 in total

Review 1.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Authors:  Nita A Limdi; Donna K Arnett; Joyce A Goldstein; T Mark Beasley; Gerald McGwin; Brian K Adler; Ronald T Acton
Journal:  Pharmacogenomics       Date:  2008-05       Impact factor: 2.533

3.  Multivariate analysis of the relation between diet and warfarin dose.

Authors:  Morten Arendt Rasmussen; Jane Skov; Else-Marie Bladbjerg; Johannes J Sidelmann; Marianne Vamosi; Jørgen Jespersen
Journal:  Eur J Clin Pharmacol       Date:  2011-09-21       Impact factor: 2.953

4.  Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial.

Authors:  Alma Rut Oskarsdóttir; Brynja R Gudmundsdottir; Olafur S Indridason; Sigrun H Lund; David O Arnar; Einar S Bjornsson; Magnus K Magnusson; Hulda M Jensdottir; Brynjar Vidarsson; Charles W Francis; Pall T Onundarson
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

Review 5.  Potential interactions between exercise and drug therapy.

Authors:  Thomas L Lenz; Nancy J Lenz; Michele A Faulkner
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

6.  Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications.

Authors:  Aditi Shendre; Timothy Mark Beasley; Todd M Brown; Charles E Hill; Donna K Arnett; Nita A Limdi
Journal:  Pharmacotherapy       Date:  2014-06       Impact factor: 4.705

7.  Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Authors:  N A Limdi; G McGwin; J A Goldstein; T M Beasley; D K Arnett; B K Adler; M F Baird; R T Acton
Journal:  Clin Pharmacol Ther       Date:  2007-07-25       Impact factor: 6.875

8.  Acute physical exercise is safe in patients with primary antiphospholipid syndrome with exclusive venous thrombosis and under oral anticoagulation with warfarin.

Authors:  Carolina Borges Garcia; Luciana Parente Costa Seguro; Luiz Augusto Perandini; Ana Lúcia de Sá Pinto; Fernanda Rodrigues Lima; Carlos Eduardo Negrão; Eloisa Bonfa; Eduardo Ferreira Borba
Journal:  Rheumatol Int       Date:  2014-05-14       Impact factor: 2.631

9.  Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.

Authors:  Na Limdi; Ja Goldstein; Ja Blaisdell; Tm Beasley; Ca Rivers; Rt Acton
Journal:  Per Med       Date:  2007-05-01       Impact factor: 2.512

10.  Impact of regular physical activity on weekly warfarin dose requirement.

Authors:  Étienne Rouleau-Mailloux; Payman Shahabi; Stéphanie Dumas; Yassamin Feroz Zada; Sylvie Provost; Jason Hu; Jacqueline Nguyen; Nawal Bouchama; Ian Mongrain; Mario Talajic; Jean-Claude Tardif; Sylvie Perreault; Marie-Pierre Dubé
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.